In fact, CD33 was soon identified as a potential target receptor displayed by AML LSC, and a number of previous and recent studies have shown that this antigen is a clinically useful therapeutic target [35,36,67,68,69,70,71,72]. Here, CD33 is linked to acute myeloid leukemia.